drugset / Trial / NCT03842488
Raltegravir One Thousand Two Hundred vs Darunavir-cb in Immnunosupressed Patients: ROTDIP Study
Phase 4
Unknown
75 enrolled
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Merck Sharp & Dohme LLC · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Multicenter, randomized, open label pilot clinical trial with two parallel arms aimed to compare the efficacy of Raltegravir (RAL) 1200mg QD vs Darunavir/Cobicistat (DRV-cb) 800-150mg QD both in combination with alafenamide/emtricitabine (TAF/FTC) in patients with Human Inmunodefficiency Virus (HIV) infection and CD4\<200 cells/microL
Timeline
- Start
- 2019-04
- Primary completion
- 2021-03
- Completion
- 2021-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cobicistat | Small molecule | 150 mg | Oral |
| Comparator | Darunavir | Small molecule | 800 mg | Oral |
| Subject | Raltegravir | Other / unclassified | 1200 mg | Oral |